Evolent Health Q3 2026: Revenue Misses Expectations, Medical Costs Climb, Guidance Raised

As seen on the 24/7 Wall St. homepage on November 5, 2026.

EVH Evolent Health
Q3 2026
EPS
$0.06
est $0.06 +0.0%
Revenue
$725M
est $727M -0.2%

The medical expense ratio jumped to 93.0% from 85.0%, shrinking adjusted EBITDA to $34.3 million even as oncology launches nearly doubled Performance Suite revenue. Management still raised full-year adjusted EBITDA guidance to $130 million to $135 million. How fast that margin recovers is the whole story.

Continue ReadingShow less

Evolent Health reported Q3 2026 revenue of $725.4 million, missing expectations of $727.1 million. Revenue still rose 51.3% year over year, a pace almost entirely driven by the company's risk-based Performance Suite, which nearly doubled revenue to $564.3 million from $286.9 million in the same quarter a year earlier.

The engine behind that Performance Suite growth was a wave of oncology launches that pushed the average per-member-per-month fee to $26.14 from $14.77 a year ago. Lives under management in the segment also grew, reaching 7,195 thousand from 6,474 thousand. More members paying a higher rate lifted the top line while adding medical cost exposure.

The Medical Expense Ratio climbed to 93.0% from 85.0% a year ago. That eight-percentage-point swing compressed Adjusted EBITDA to $34.3 million from $39.0 million, even as revenues expanded. For a company in the business of managing specialty care costs on behalf of health plans, the pace at which that ratio comes back down is the central question investors will be asking.

Sponsored

Despite the margin pressure, management raised its full-year 2026 Adjusted EBITDA guidance to $130.0 million to $135.0 million, while reiterating the full-year revenue range of $2.6 billion to $2.7 billion. The confidence appears rooted in a January 2027 oncology expansion covering roughly 1 million additional Commercial lives from an existing client, as well as seven new revenue agreements and renewals signed year to date.

CEO Seth Blackley pointed to the company's AI platform and oncology solution as the drivers of future margin expansion, stating that he believes they will drive growth in coming quarters. GAAP net loss attributable to common shareholders narrowed to $23.6 million from $26.9 million a year earlier, and cash and equivalents stood at $148.3 million, up 27.1% year over year. The company also said it intends to deploy up to $50 million toward reducing outstanding debt by year-end.

Mentioned: EVH